Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Fear of Pfizer-AstraZeneca job cuts voiced by U.S. lawmakers

Published 10/05/2014, 22:01
Updated 10/05/2014, 22:16
PFE
-

By Patrick Temple-West

WASHINGTON (Reuters) - Members of the U.S. Congress from Maryland and Massachusetts expressed concern on Saturday that thousands of jobs in their districts could be at risk if U.S. drugmaker Pfizer Inc (N:PFE) completes a buyout of UK-based AstraZeneca Plc .

"The scale of this is really causing people to pay attention. I’m really concerned about it," said Democratic Representative John Delaney, whose Maryland district includes a 3,000-worker facility of AstraZeneca's MedImmune unit.

His remarks came as Pfizer tried to allay worries in the United States and Britain about layoffs possibly resulting from its $106-billion bid for its UK rival, in what would be the largest-ever foreign takeover of a British company.

AstraZeneca so far has spurned Pfizer, which has a history of big job cuts after past acquisitions. The U.S. company was considering its next move, possibly a sweetened offer.

Representative Delaney said in an interview: "We encourage Pfizer to look hard at the MedImmune asset and hopefully get comfortable that this is something they’d want to keep here."

Democratic Massachusetts Representative Katherine Clark said AstraZeneca has hundreds of jobs in her Boston-area district.

"I am working to ensure that these good jobs are retained and that our communities can continue to count on a good corporate neighbour," she told Reuters in an email.

Pfizer understands and appreciates the concerns of the members of Congress, company spokesman MacKay Jimeson said in an email.

"We believe a potential combination with AstraZeneca would build a stronger company by bringing together our assets, people and scientific expertise," Jimeson said.

The governors of Maryland and Delaware on Thursday sent a letter to Pfizer Chief Executive Ian Read "expressing deep concerns" about the impact of the deal on jobs, as well as Pfizer's plan to relocate its corporate base to Britain to lower its taxes. AstraZeneca employs 2,600 people in Delaware, the letter said.

Britain's No. 2 drugmaker, AstraZeneca has employees in the districts of more than a dozen members of Congress, including Republican House Speaker John Boehner of Ohio.

(Additional Ben Hirschler in London; Editing by Kevin Drawbaugh and Marguerita Choy)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.